Johnson & Johnson (JNJ)
Verdict history · JNJ
Every call Verdix has made on JNJ.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
In August, the panel was unanimous at WAIT with high conviction, anchored around a $260 price and a forward P/E that already looked full. Since then, the stock has crept another 3.8% higher into overbought territory, insider selling has continued with zero offsetting purchases, and the TCPA class-action reversal has reintroduced a legal uncertainty that wasn't live three months ago. The panel stays neutral, but the dissent now has a voice — The Asymmetric Bargainer — who argues the asymmetry has tipped negative, while the five hold signals remain cautious because the business hasn't deteriorated, only the price has gotten marginally worse.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on JNJ — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
NYSE · Health Care / Pharmaceuticals & MedTech · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
JNJ's business quality is not in dispute — six analytical frameworks all recognize a wide-moat healthcare compounder with strong cash flows. The debate is purely about price: at 31x trailing earnings, with insiders selling $26M near all-time highs and the consensus target offering less than 1% upside, the panel holds at neutral and waits for a pullback that would restore a margin of safety.Level to watch
Key resistance 276.47+2.3% from 270.24
Next catalyst
Key support to watch: A weekly close below the EMA20 at $247.65 would confirm trend weakening and shift the panel's bias from neutral to outright bearish.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 270.24 · Changed from WAIT
Panel: 0 Bullish · 5 Neutral · 1 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 260.35 → 270.24 (+3.80%)
- Panel: 0 of 6 → 0 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer; removed The Scuttlebutt Growth Investor
- Trigger: A pullback to the $247–252 zone restores a margin of safety (forward P/E below 22) and would shift the panel to BUY. On the downside, a weekly close below the EMA20 at $247.65 would confirm trend weakening and shift it to SELL.
- Verdict: WAIT → BALANCED
In August, the panel was unanimous at WAIT with high conviction, anchored around a $260 price and a forward P/E that already looked full. Since then, the stock has crept another 3.8% higher into overbought territory, insider selling has continued with zero offsetting purchases, and the TCPA class-action reversal has reintroduced a legal uncertainty that wasn't live three months ago. The panel stays neutral, but the dissent now has a voice — The Asymmetric Bargainer — who argues the asymmetry has tipped negative, while the five hold signals remain cautious because the business hasn't deteriorated, only the price has gotten marginally worse.
Five voices find the business wonderful but the price stretched — trailing P/E at 31x vs. a 10-year median of 22x, consensus target implying +0.84% upside, and $26M in insider selling near the ATH — so the asymmetry is balanced. The lone bear (The Asymmetric Bargainer) argues the expected value is negative, but his objection is a price/timing call (pullback to $200–225), not a business-quality strike, and one dissent is not enough to tip the panel from a 5–1 neutral majority.
Key levels
Key levels · JNJ
USD · as of 2026-08-22Analyst consensus target 272.5 USD · range 190–305
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance is the all-time high at $276.47 — only $6 away and untested; a weekly close above it would break the bear case. Key support at $247.65 is the weekly EMA20, which has held the entire Stage 2 advance and converges with the 23.6% Fibonacci retracement at $252.13 — that band is the first logical landing zone for a pullback. The historical accumulation zone sits far below at $186–189 (old monthly resistance turned support near the EMA200), reflecting how much of the rally has occurred on thinning volume. The analyst consensus target of $272.50 sits just 0.8% above the current price, reinforcing how fully valued the stock is.
What legendary investors think
We ran Johnson & Johnson past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: Trailing P/E of 31 sits well above the 10-year median of 22, and with a base-case DCF landing near $255, the stock at $270 offers a margin of safety of roughly negative 6% — you are paying for the bull case without evidence it will materialize. Conviction: Conviction is constrained because the DCF range spans from $245 to $285 depending on WACC and margin assumptions, and without exact operating margin or reinvestment-efficiency data, the fair-value estimate remains a wide band rather than a tight number.
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: JNJ earns an earnings yield of just 3.2% against a 10-year Treasury at 4.7%, so the stock offers no margin of safety relative to the risk-free rate even though the moat — patent-protected pharmaceuticals, switching costs in devices, and 63 years of rising dividends — scores a 9 out of 10. Conviction: Conviction stays high that this is not a buy because the price signal is unambiguous: an earnings yield below Treasuries plus zero insider buying and $26M in insider selling at the highs leaves no way to justify paying up.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: Operating cash flow covers net income at 1.31x, so the earnings are real, but $26M in insider sales with zero purchases near the 52-week high is the single most telling data point in the file — it signals that those closest to the business see it as fully priced. Conviction: Conviction is held back because the tangible book value and litigation-reserve figures are not in evidence; known unknowns like the TCPA class action could shift the intrinsic-value math materially once quantified.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The PEG ratio sits at roughly 1.93 on a 12.4% three-year EPS growth rate, and with the volume profile showing most trading clustered at $140–$174 while price floats in thin air above $210, the easy money has already been made. Conviction: Confidence is modest because a PEG near 2.0 for a Stalwart is simply not cheap: I can wait indefinitely for a pullback to the $247–$252 zone while the dividend keeps paying, and I lose nothing by being patient.
The Asymmetric BargainerContrarian/Deep Value🔴 BearishMed
Signal: The Dhandho framework fails three of four tests — the expected value is negative because a re-rate to the historical 22x P/E implies roughly 30% downside, while the consensus target offers less than 1% upside — so this is heads I lose a lot, tails I win a little. Conviction: Conviction runs at 65% because the downside math is straightforward and the insider-selling signal corroborates it, though a sudden pipeline breakthrough would be the one low-probability event that invalidates the asymmetry.
The Quality RationalistMental Models/Quality⚫ NeutralLow
Signal: ROIC of nearly 20% and an FCF margin of 22.7% confirm the business is wonderful, but management's own FY2026 guidance midpoint of $11.125 sits below the consensus estimate of $11.62, and when the insiders are less optimistic than the Street, I side with the insiders. Conviction: Conviction is held in check because the business-quality score is genuinely high, and a 15–20% pullback would flip this into a comfortable holding; the current price is the only real objection.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six voices agree JNJ is a high-quality, wide-moat business with strong cash generation and a conservative balance sheet — nobody disputes the fundamental strength of the enterprise.
- Five of six see the current valuation as stretched: trailing P/E above 31 versus a 10-year median near 22, consensus target implying less than 1% upside, and earnings yield below the risk-free rate.
- Every archetype flags the $26M in insider selling with zero insider purchases as a meaningful signal that management considers the stock fully valued near all-time highs.
- The panel unanimously views a pullback — whether to $247–$252 or deeper to $200–$225 — as the condition that would dramatically improve the setup, not because the business would change but because the price would finally offer a cushion.
The real debate
- The Asymmetric Bargainer is the sole bear, arguing the expected value is outright negative with a 30% downside to the historical P/E, while the other five voices view the stock as overpriced but not broken — a timing objection rather than a business-quality strike.
- The Intrinsic-Value Modeler and The Forensic Skeptic both anchor fair value near $255–$265, yet they disagree on what the largest risk is: the Modeler worries about margin assumptions and WACC sensitivity, while the Skeptic sees the unquantified TCPA legal overhang as the true wildcard.
- The Moat Compounder and The Quality Rationalist both admire the business deeply (moat scores of 9/10), but they diverge on the weight of the insider signal — the Compounder treats it as a straightforward price caution, while the Rationalist layers on the management-versus-consensus guidance gap as an additional reason to hesitate.
The question it comes down to: Is the premium valuation — 31x trailing earnings with insiders selling at the highs — a temporary condition that patience will resolve with a pullback, or the early signal of a growth deceleration that will make even lower prices look expensive?
The bottom line
- Key support to watch: A weekly close below the EMA20 at $247.65 would confirm trend weakening and shift the panel's bias from neutral to outright bearish.
- Trigger for a bullish turn: A pullback into the $247–$252 zone restores a forward P/E below 22 and would shift five of six voices to a buy signal, especially if accompanied by even one insider purchase.
- Next catalyst: Q3 2026 earnings in mid-October: consensus expects a slight beat, but management's own guidance sits below Street estimates, and any miss would validate the insider-selling signal and accelerate multiple compression.
- Risk to monitor: The revived TCPA class action introduces an unquantified legal liability; a settlement announcement or adverse ruling would directly reduce the cash-flow base that every valuation case depends on.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in JNJ · JNJ verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.